4TH ANNUAL BREAST CANCER SYMPOSIUM
LIVE IN PERSON AND ONLINE BROADCAST
The fee for this educational activity is $250 for physicians (MD/DO), $150 for advanced practice professionals (NP/PA) and $50 for all other allied health professionals (RNs/Other). The fee for Industry participants is $500.
The 4th Annual Breast Cancer Symposium titled: OPENING DOORS: Lab to Clinic to Patient is being organized in collaboration with New York Oncology Hematology (NYOH), The University of Chicago Pritzker School of Medicine, and myMedEd, Inc. This accredited conference will offer 16.5 continuing education credits and is scheduled to be held live in person September 23-25, 2022 at the Hudson Hall in Hudson, NY and as an online live broadcast at nyohbcs.org.
The 4th Annual Breast Cancer Symposium is being held live in person and online via a live broadcast. The sponsors and exhibitors of the conference will be available for attendees to visit during the duration of the conference in both platforms.
Advances in our understanding of the genetic and physiologic pathways of breast cancer have led to the development of targeted systemic therapies, improved surgical procedures, and radiation techniques, and improved, disease-free, and overall survival benefits. The goal of this conference is to educate the medical and global community in a forum that will facilitate the utilization of optimal treatment strategies and foster communication that will benefit the individual patient as well as the community.
Medical, surgical, and radiation oncologists as well as primary care physicians, gynecologists, medical professionals and health care professionals with an interest in breast cancer are invited to attend.
After completing this activity, participants will be able to:
- Review the recent developments in breast surgical approaches including upfront and after neoadjuvant chemotherapy
- Explain the rationale for reconstruction options post neoadjuvant chemotherapy and radiation therapy
- Discuss updates in breast cancer imaging for earlier detection
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2 neu overexpressing, and triple-negative breast cancer
- Review the advances in radiation therapy and outcomes including short-course radiation therapy and de-escalation
- Describe the management of HER2 positive early breast cancer in the older patient
- Review the treatment of early-stage inherited breast cancer
- Identify the new and emerging systemic treatment options for breast cancer brain metastases beyond surgery and radiotherapy
- Describe molecular profiling for metastatic breast cancer management
- Explain the mechanism of action and rationale for immunotherapy
This Activity Is Planned By myMedEd, Inc.